Description overdue on 12.08.2012
- Enterofuril, reviews and price
- Indications Reamberin
- Lorista
- Mezaton
Remedy for Hemorrhoids . The active components are fluocortolone (glucocorticosteroid) tsihokain and klemizol . The drug ultraprokt has antipruritic, anti-inflammatory, antihistamine, anti-allergic, and local anesthetic effects. Tsinokain provides local anesthetic effect, reduces the severity of klemizol itching and inflammation due to antihistamine influence . Fluocortolone can prevent the accumulation of neutrophils boundary, which reduces the production of cytokines and the production of inflammatory exudate. Fluocortolone reduces the rate of granulation infiltration macrophage migration . Ultraprokt available as a rectal suppository and ointment for topical use.
Indications, contraindications:
Ultraprokt prescribed for hemorrhoids (internal and external forms), with proctitis , Cracks in the anus, itching in the anal area. The drug is not prescribed for syphilitic, tuberculous processes anorectal area and rectum, pregnancy, intolerance fluocortolone, klemizola, tsihokaina.
Side effect:
Ultraprokt can cause hypopigmentation, telangiectasia , Dry skin, burning, itching . Long-term therapy is skin atrophy .
Mode of application:
Ultraprokt administered rectally. The recommended dose - 1 suppository per day, with severe disease, the introduction of up to three suppositories, but no more. Ultraprokt ointment applied twice daily a thin layer, for more rapid achievement of the result ointment can be applied up to 4 times per day. Drug therapy was continued for one week after the disappearance of the main manifestations of the disease: 1 suppository every other day or 1 application of ointment per day. Not recommended therapy for more than 4 weeks. Suppositories and ointment can be used further after each act of defecation. Treatment of inflammatory processes include simultaneous treatment of candles and ointment. No clinically significant drug interactions drug ultraprokt and other medicines have been reported.
No comments:
Post a Comment